Short Interest in Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) Rises By 21.8%

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 6,269,500 shares, an increase of 21.8% from the August 15th total of 5,149,100 shares. Based on an average daily trading volume, of 200 shares, the days-to-cover ratio is currently 31,347.5 days.

Ono Pharmaceutical Stock Performance

OTCMKTS:OPHLF remained flat at $15.50 during mid-day trading on Monday. Ono Pharmaceutical has a 52-week low of $12.66 and a 52-week high of $19.39. The business has a fifty day moving average price of $14.08 and a two-hundred day moving average price of $14.78.

Ono Pharmaceutical (OTCMKTS:OPHLF) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.34 EPS for the quarter. The firm had revenue of $754.85 million during the quarter. Ono Pharmaceutical had a net margin of 24.26% and a return on equity of 14.95%. Equities research analysts forecast that Ono Pharmaceutical will post 1.44 EPS for the current fiscal year.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.